ID   NCC-LMS2-C1
AC   CVCL_A4EE
DR   Wikidata; Q105510289
RX   PubMed=33001379;
WW   https://en.cellline.jp/product/ncc-lms2-c1/
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Senescence: It is possible that this cell line is not immortal and has a finite life span (personal communication of Kondo T.).
CC   Doubling time: 46 hours (PubMed=33001379).
CC   Derived from site: Metastatic; Thigh; UBERON=UBERON_0000376.
ST   Source(s): PubMed=33001379
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11,13
ST   D16S539: 9
ST   D21S11: 29
ST   D5S818: 13
ST   D7S820: 12
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C3158; Leiomyosarcoma
DI   ORDO; Orphanet_64720; Leiomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   90Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 30-01-24; Version: 6
//
RX   PubMed=33001379; DOI=10.1007/s13577-020-00443-6;
RA   Noguchi R., Yoshimatsu Y., Ono T., Sei A., Hirabayashi K., Ozawa I.,
RA   Kikuta K., Kondo T.;
RT   "Establishment and characterization of NCC-LMS2-C1-a novel
RT   patient-derived cancer cell line of leiomyosarcoma.";
RL   Hum. Cell 34:279-288(2021).
//